INTRAOPERATIVE PHOTODYNAMIC THERAPY FOR PERITONEAL MESOTHELIOMA

Abstract Results of application of a new technology of intraoperative photodynamic therapy (IOFDT) in patients with peritoneal mesothelioma developed at P. Herzen Moscow Oncology Research Institute are presented. The study included 8 patients. 3 patients underwent surgery in various amount: 1 – limited peritonectomy in the volume of tumor foci resection and resection of a large omentum, 1 – limited peritonectomy in the volume of tumor foci resection and atypical resection of the right lobe of the liver, 1 – only resection of the large omentum due to the fact that the tumor was located only in a large omentum and no signs of lesions of the parietal peritoneum was revealed by intraoperative revision. Surgical intervention in these patients was concluded by IOPDT. The remaining 5 patients underwent only IOPDT. After the treatment, two patients underwent additional courses of laparoscopic IOPDT. Of the 8 patients enrolled in the study, 4 died from the underlying disease, 1 from cardiovascular disease with recurrence of the disease, 1 from cardiovascular disease without signs of recurrence, 2 were monitored for 6 months and 146 months (12 years). Thus, in the group of patients with peritoneal mesothelioma, the maximum observation period was 146.44 months, the median survival was 48.4 months, the total specific 1-year survival was 85.7±13.2%, the three-year survival was 68.5±18.6%, the 5-year survival was 45.7 ± 22.4 %. The average life expectancy after treatment of patients with repeated courses of laparoscopic IOPDT was 87 months, without repeated courses – 35.8 months. Thus, life expectancy was higher in patients with repeated courses of laparoscopic IOPDT. Small sample size caused to the rarity of this pathology does not allow for statistically significant conclusions. However, the results of the study indicate the prospects of multi-course intraoperative photodynamic therapy in patients with peritoneal mesothelioma.

intraoperative photodynamic therapy, peritoneal mesothelioma

1. Van Baal J.O., Van de Vijver K.K., Nieuwland R., van Noorden C.J., van Driel W.J., Sturk A., Kenter G.G., Rikkert L.G., Lok C.A. The histophysiology and pathophysiology of the peritoneum, Tissue Cell, 2017, Vol. 49(1), pp. 95-105.

2. Muzalevskii P.N., Shoikhet Ya.N., Lazarev A.F., Grigoruk O.G. Mesothelioma: prevalence and modifying factors (literature review), Sibirskii onkologicheskii zhurnal, 2007, No. 2, pp. 77-83.

3. Soeberg M.J., Creighton N., Currow D.C., Young J.M., van Zandwijk N. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009, Aust N Z J Public Health, 2016, Vol. 40(3), pp. 255-262.

4. Stolnicu S., Quiñonez E., Boros M., Molnar C., Dulcey I., Nogales F.F. Case report: Papillary mesothelioma of the peritoneum with foamy cell lining, Diagnostic pathology, 2013, Vol. 8, p. 162.

5. Sugarbaker S.H. Two Decades of Progress in the Management of a Rare Disease – Peritoneal Mesothelioma, Oncology & Hematology Review, 2015, Vol. 11(1), pp. 67-73.

6. Mossman B.T., Shukla A., Heintz N.H., Verschraegen C.F., Thomas A., Hassan R. New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas, The American Journal of Pathology, 2013, Vol. 182(4), pp. 1065-1077.

7. Lim J.Y., Wolf A.S., Flores R.M. The use of surgery in mesothelioma, Lancet Respir Med, 2013, Vol. 1(3), pp. 184-186.

8. Lee Y.K., Jun H.J., Nahm J.H., Lim T.S., Park J.S., Ahn J.B., Rha S.Y., Chung H.C., Oh H.E., Song J.S., Yang W.I., Kim H.S. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum, Jpn J Clin Oncol, 2013, Vol. 43(10), pp. 996-1003.